Abstract: Solution administrable by intravascular injection in a human or an animal which comprises an effective amount up to 0.23% by weight of a benzalkonium fluoride having the formula: ##STR1## where R is an alkyl radical which may vary between C.sub.8 H.sub.17 and C.sub.18 H.sub.37, dissolved in an excipient injectable intravascularly. Preferably R is between C.sub.12 H.sub.25 and C.sub.14 H.sub.29, and more preferably C.sub.14 H.sub.29. The solution can be packaged in 10 ml ampoules, containing about 21 mg of benzalkonium fluoride, the benzalkonium fluoride being dissolved in a physiological solvent. The solution also contains at least one metallic derivative of fluorine, preferably lithium fluoride.

Abstract: A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering a retinoid, such as an RAR-selective retinoid, e.g.

Abstract: A pharmaceutical agent contains a progesterone synthesis inhibitor (ProI) of the trilostane or epostane type and an antigestagen (AG). It can be used for inducing delivery at term in humans and animals, for terminating normal or pathological pregnancies therein or for treatment of hormone-dependent tumors, endometriosis or dysmenorrhea.

Abstract: The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein R.sup.1 is hydrogen, fluoro, or chloro, and R.sup.2 is hydrogen or methyl. The above compounds are lipoxygenase inhibitors. The invention also relates to pharmaceutical compositions containing the above compounds, and to methods of treating inflammatory and allergic conditions by administering the above compounds.

Abstract: Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).

Abstract: Methods and compositions are disclosed utilizing the optically pure (+) isomer of zopiclone. This compound is a potent drug for the treatment of sleep disorders, such as insomnia, and convulsive disorders, such as epilepsy. Similarly, these novel compositions and methods are useful for the treatment of sleep disorders and convulsive disorders while avoiding the concomitant liability of adverse effects associated with the racemic mixture of zopiclone. The optically pure (+) isomer of zopiclone is also useful for treating disorders that are affected by the binding of agonists to central nervous system or peripheral benzodiazepine receptors. Also described are methods and compositions for treating disorders that are affected by binding of agonists to central nervous system or peripheral benzodiazepine receptors while avoiding the adverse effects associated with the administration of the racemic mixture of zopiclone.

Abstract: Methods whereby the narcotic antagonist 17-(cyclopropylmethyl)-4,5alpha-6-methylenemorphinan-3,14-diol,hydrochlori de salt and other narcotic antagonists are used for chemically precipitating a withdrawal response in human beings addicted to exogenous narcotics and who are currently using exogenous narcotics.

Abstract: The present invention relates to methods of treating, as well as preventing extravasation injury. In particular, the present invention pertains to photochemotherapeutic methods of prophylaxis and/or treatment of extravasation injury induced by vesicant antineoplastic drugs and other pharmaceutical formulations. In accordance with the present invention, extravasation injury is prevented or minimized by the coadministration of photoinactivation inducing compounds in a formulation comprising a vesicant antineoplastic or other pharmaceutical formulation, and subsequently exposing the injection or infusion site to photoexciting light.

Abstract: For the purpose of providing a composition having an ability of promoting degradation of accumulated cellular fats, a substance having such ability was developed from naturally-occurring safe materials. Thus, according to the present invention, a composition for promoting fat-degradation in a fat cell comprising containing an isoflavone in an amount effective to promote the fat-degradation in said fat cell.

Abstract: This invention relates to a method of treating a patient in need of relief from convulsions which comprises administering to such a patient a convulsion-alleviating amount of a compound of the formula ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, m and n are as defined within.

Abstract: A composition for topical therapy for symptoms of back pain, muscle tension or myofascial pain or a combination thereof, which comprises a topical carrier system for intact skin of the back or outer synovial membranes or both, which comprises a therapeutic dose of a local anesthetic, and which applies the local anesthetic to a region of skin lying beneath the topical carrier system.

Abstract: A method of lowering plasma levels of Lp(a) or inhibiting the generation of apo(a) in a human by administering an effective amount of a compound of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or alkyl;A, B, D, E, G, R.sup.2 and R.sup.3 each are hydrogen, and R.sup.4 is hydrogen in the .beta.-position; orR.sup.2 with R.sup.4, R.sup.4 with A, A with R.sup.3, B with D, D with E, or G with R.sup.2 is a bond, and the other substituents are each hydrogen; orR.sup.2 is alkyl in the .beta.-position and A, B, D, E, G, R.sup.3 and R.sup.4 are each hydrogen; orR.sup.3 is alkoxy in the .beta.-position and A, B, D, E, G, R.sup.2 and R.sup.4 are each hydrogen; orR.sup.4 is hydrogen in the .alpha.-position and A, B, D, E, G, R.sup.2 and R.sup.3 are each hydrogen; andR.sup.5 is methyl or ethyl, is disclosed.

Abstract: The invention is directed to the use of 5HT.sub.3 antagonists of formula I ##STR1## wherein the substituents are as defined herein.

Abstract: A method for restoring reproductive function in a reproductively impaired male or female host is disclosed, the method comprising administering a leptin compound to the host for a time and in an amount sufficient to restore or enhance reproductive function. A method of accelerating the onset of puberty in a male or female host is also disclosed, the method comprising administering a leptin compound to the host for a time and in an amount sufficient to cause the onset of puberty.

Abstract: Body oils of all natural ingredients are disclosed having a base oil, such as virgin olive oil, which serves as a carrier for flavoring(s) or fragrance(s), sensory material(s), and optionally a sweetener. Application of the oil provides sensory stimulation and is not harmful upon ingestion.

Abstract: A hormone replacement composition, a hormone replacement dosage form, and a method of hormone replacement are disclosed and indicated for the management of hormone replacement therapy.

Abstract: The present invention concerns cool-water dispersible powder formulations of high molecular weight hydroxypropyl methylcellulose which has been milled to a specified particle size, with or without encrustation or other surface treatment, for dispersion into consumable liquids or for formulation of dry-mix powders, sauces, instant set puddings and baked goods for human consumption. The formulation is used for reduction of serum cholesterol levels. A process for preparing the formulation and its mode of administration is also provided.

Abstract: The application relates to the use of bromelain in the treatment of hypercholesterolaemia and similar diseases. Bromelain is able to act as a bile acid receptor antagonist and therefore to prevent reabsorption of bile acids by the gastrointestinal tract.

Abstract: The present invention is a pharmaceutical composition having a combination of an uricosuric agent such as probenecid or the like and an excitatory amino acid antagonist useful for treating a disease advantageously affected by treatment with an excitatory amino acid antagonist.

Abstract: Selective blockade of DA and 5-HT uptake sites with 3-aryltropane derivatives.